Vittia Annual Report 2022
VITTIA
Investments in CAPEX and in Research, Development, and Innovation
0000
Investments in CAPEX were BRL 61.3 million
in 2022 (+17.6% above 2021). The increase is
mainly a reflection of investments in the new
Storage and Shipping Center, expansion of the
biological defensive plant, expansion of
inoculant production capacity and the transfer
and expansion of production of nitrates and
phosphites. Highlights:
Storage and Shipping Center
In 2022, BRL 10.0 million were invested in the
Storage and Shipping Center, located in the
municipality of São Joaquim da Barra (SP),
totaling BRL 31.3 million invested in Phase 1.
The unit started operating in June 2022,
shortly after the release of the Fire Department
Inspection Report (AVCB). With a projected
capacity for 14,000 pallet points, this
investment provided a 123% increase in Vittia's
capacity for pallet positions, reaching 25,400.
In addition to the increase in capacity, we also
had significant gains in control, operational
efficiency, safety, and customer service.
For 2023, we have an investment in Phase 2,
focusing on cold storage. The planned
investment is BRL 9.2 million, for the
construction of a cold room with 2,118 positions
and increase in the storage capacity of the
Storage and Dispatch Center by over 2,100
pallet points, totaling 27,500 pallet points.
Expansion of the biological defensive plant
Investments in the plant, in 2022, amounted to BRL
16.6 million, out of a total of BRL 20.1 million budgeted
for doubling the production capacity of solid
fermentation and increasing operational flexibility,
enabling simultaneous and safe production of a
greater number of microorganisms/products (with
lower risk of losses due to contamination). These
investments refer to Phase 2 of the project, scheduled
for completion in the second quarter of 2023.
Expansion of inoculant production capacity
BRL 2.7 million were invested in 2022, out of a
total of BRL 2.8 million planned, to expand the
production capacity of inoculants, from the
current 35 million doses/year to 44 million
doses/year.
Research, Development, and Innovation
In 2022, the amount invested was BRL 25.8
million, an increase of 57.5% compared to the
previous year, representing 3.0% of the
Company's net revenue (+0.9 p.p. above 2021).
Annual Report 2022
119View entire presentation